Clinical Trials Browser

NCT02257736 2026-03-19

An Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)

Phase 3 Active not recruiting

982 enrolled 15 charts

Genitourinary

Prostatic Neoplasms

NCT02531516 2026-03-19

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

Phase 3 Active not recruiting

1,503 enrolled

Genitourinary

Prostatic Neoplasms

NCT04579224 2026-03-19

Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer

Phase 3 Active not recruiting

184 enrolled

Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04658862 2026-03-19

SunRISe-2

Phase 3 Active not recruiting

518 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT05092958 2026-03-19

Testing the Addition of the Anti-cancer Drug, Cabozantinib, to the Usual Immunotherapy Treatment, Avelumab, in Patients With Metastatic Urothelial Cancer, MAIN-CAV Study

Phase 3 Active not recruiting

654 enrolled

Genitourinary

Urinary Bladder Neoplasms, Ureteral Neoplasms, Urethral Neoplasms

NCT05714202 2026-03-19

SunRISe-3

Phase 3 Active not recruiting

1,135 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT01575548 2026-03-18

Pazopanib Hydrochloride in Treating Patients With Metastatic Kidney Cancer Who Have No Evidence of Disease After Surgery

Phase 3 Active not recruiting

129 enrolled 11 charts

Genitourinary

Carcinoma, Renal Cell

NCT03775265 2026-03-18

Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

475 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03793166 2026-03-18

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Phase 3 Active not recruiting

1,175 enrolled

Genitourinary

Carcinoma, Renal Cell, Lymphatic Metastasis

NCT03055013 2026-03-17

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Phase 3 Active not recruiting

819 enrolled 12 charts

Genitourinary

Carcinoma, Renal Cell

NCT05794906 2026-03-17

ARASTEP

Phase 3 Active not recruiting

985 enrolled

Genitourinary

Biochemically Recurrent Prostate Cancer

NCT06211764 2026-03-17

SunRISe-5

Phase 3 Active not recruiting

272 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT07477626 2026-03-17

RADVAN

Phase 3 Active not recruiting

374 enrolled

Genitourinary

Prostatic Neoplasms

NCT03748641 2026-03-16

MAGNITUDE

Phase 3 Active not recruiting

765 enrolled 16 charts 1 FDA

Genitourinary

Prostatic Neoplasms, Castration-Resistant

NCT04452591 2026-03-16

BOND-003

Phase 3 Active not recruiting

190 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Carcinoma in Situ

NCT03732677 2026-03-13

NIAGARA

Phase 3 Active not recruiting

1,063 enrolled 15 charts 1 FDA

Genitourinary

Urinary Bladder Neoplasms

NCT04557059 2026-03-13

PRIMORDIUM

Phase 3 Active not recruiting

693 enrolled

Genitourinary

Prostatic Neoplasms

NCT05884398 2026-03-12

LIBERTAS

Phase 3 Active not recruiting

420 enrolled

Genitourinary

Metastatic Castrate-sensitive Prostate Cancer

NCT04720157 2026-03-11

PSMAddition

Phase 3 Active not recruiting

1,145 enrolled

Genitourinary

Prostatic Neoplasms

NCT04821622 2026-03-11

Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC

Phase 3 Active not recruiting

599 enrolled

Genitourinary

Prostatic Neoplasms

NCT05171816 2026-03-11

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (China Cohort)

Phase 3 Active not recruiting

110 enrolled 12 charts

Genitourinary

Metastatic Castration-resistant Prostate Cancer

NCT07000149 2026-03-10

eVOLVE-RCC02

Phase 3 Active not recruiting

1,116 enrolled

Genitourinary

Diabetes Mellitus, Insulin-Dependent, 12, Carcinoma, Renal Cell, Kidney Neoplasms

NCT03036098 2026-03-06

CheckMate901

Phase 3 Active not recruiting

1,314 enrolled 23 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT05154162 2026-03-03

PRIMARY2

Phase 3 Active not recruiting

660 enrolled

Genitourinary

Neoplasms, Prostatic Neoplasms

NCT04484818 2026-03-02

Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study

Phase 3 Active not recruiting

27 enrolled

Genitourinary

Prostatic Neoplasms

NCT05538663 2026-03-02

BRIDGE

Phase 3 Active not recruiting

870 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms

NCT05863351 2026-03-02

Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study

Phase 3 Active not recruiting

472 enrolled

Genitourinary

Carcinoma, Renal Cell

NCT03574571 2026-02-27

A Study to Test Radium-223 With Docetaxel in Patients With Prostate Cancer

Phase 3 Active not recruiting

732 enrolled

Genitourinary

Prostatic Neoplasms

NCT02811861 2026-02-23

CLEAR

Phase 3 Active not recruiting

1,069 enrolled 12 charts 1 FDA

Genitourinary

Carcinoma, Renal Cell

NCT04689828 2026-02-20

PSMAfore

Phase 3 Active not recruiting

469 enrolled 11 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT04497844 2026-02-13

AMPLITUDE

Phase 3 Active not recruiting

696 enrolled 15 charts 1 FDA

Genitourinary

Metastatic Castration-sensitive Prostate Cancer

NCT04660344 2026-02-13

IMvigor011

Phase 3 Active not recruiting

761 enrolled

Genitourinary

Muscle-invasive Bladder Cancer

NCT04076059 2026-02-06

China ARCHES

Phase 3 Active not recruiting

180 enrolled 24 charts

Genitourinary

Metastatic Hormone Sensitive Prostate Cancer

NCT04455750 2026-02-05

CASPAR

Phase 3 Active not recruiting

61 enrolled

Genitourinary

Prostatic Neoplasms

NCT03661320 2026-02-03

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

Phase 3 Active not recruiting

855 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT03682068 2026-02-03

NILE

Phase 3 Active not recruiting

1,246 enrolled

Genitourinary

Urinary Bladder Neoplasms

NCT01946204 2026-02-02

SPARTAN

Phase 3 Active not recruiting

1,207 enrolled 15 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT02489318 2026-02-02

TITAN

Phase 3 Active not recruiting

1,052 enrolled 13 charts 1 FDA

Genitourinary

Prostatic Neoplasms

NCT03390504 2026-02-02

THOR

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Genitourinary

Urothelial Cancer

NCT02516241 2026-01-28

Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Phase 3 Active not recruiting

1,126 enrolled 52 charts

Genitourinary

Urothelial Cancer

NCT03091192 2026-01-23

Savolitinib vs. Sunitinib in MET-driven PRCC.

Phase 3 Active not recruiting

60 enrolled 15 charts

Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

NCT04165317 2026-01-22

CREST

Phase 3 Active not recruiting

1,068 enrolled 20 charts

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms

NCT04493853 2026-01-20

CAPItello-281

Phase 3 Active not recruiting

1,012 enrolled

Genitourinary

Prostatic Neoplasms

NCT03767244 2026-01-16

PROTEUS

Phase 3 Active not recruiting

2,517 enrolled

Genitourinary

Prostatic Neoplasms

NCT03367702 2026-01-15

Stereotactic Body Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Stage IIA-B Prostate Cancer

Phase 3 Active not recruiting

692 enrolled

Genitourinary

Stage II Prostate Adenocarcinoma AJCC v7

NCT06331299 2026-01-15

UTOPIA

Phase 3 Active not recruiting

99 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04513717 2026-01-14

Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial

Phase 3 Active not recruiting

2,753 enrolled

Genitourinary

Prostatic Neoplasms

NCT04647526 2026-01-13

SPLASH

Phase 3 Active not recruiting

455 enrolled 18 charts

Genitourinary

Prostatic Neoplasms

NCT06111235 2026-01-12

A Study of Adjuvant Cretostimogene Grenadenorepvec for Treatment of Intermediate Risk NMIBC Following TURBT

Phase 3 Active not recruiting

367 enrolled

Genitourinary

Non-Muscle Invasive Bladder Neoplasms, Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Urologic Neoplasms

NCT02051218 2025-12-30

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3 Active not recruiting

1,380 enrolled

BreastGenitourinary

Breast Neoplasms, Prostatic Neoplasms